Hematology TimesApplying ECHELON-2 results to clinical practiceJanuary 31, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersT Cell Lymphomas
Hematology NewsIPH4102 on fast track for Sézary syndromeJanuary 30, 2019T Cell LymphomasLymphoma & Plasma Cell DisordersNonmelanoma Skin Cancer
Hematology TimesCombo treatment may improve quality of life in CTCLJanuary 24, 2019T Cell LymphomasLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology TimesAre single agents better than chemo for relapsed/refractory PTCL?January 24, 2019Lymphoma & Plasma Cell DisordersAggressive LymphomasT Cell Lymphomas
Hematology TimesFour-drug combo shows durable responses in relapsed/refractory lymphomasJanuary 19, 2019T Cell LymphomasAggressive LymphomasB Cell Lymphoma
Hematology TimesLong-term mogamulizumab appears safe, effective in CTCLJanuary 18, 2019T Cell LymphomasNonmelanoma Skin Cancer
Hematology TimesChidamide may be more effective in PTCL than previously thoughtJanuary 16, 2019T Cell LymphomasAggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsECHELON-2: BV-CHP boosts survival in PTCLDecember 20, 2018T Cell LymphomasAggressive LymphomasLymphoma & Plasma Cell DisordersB Cell Lymphoma
Hematology NewsFDA expands approval of brentuximab vedotin to PTCLNovember 16, 2018T Cell LymphomasLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology NewsWhen to choose stem cell transplant in PTCLOctober 24, 2018T Cell LymphomasLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology NewsAITL responds to 5-azacytidine in small seriesOctober 5, 2018T Cell LymphomasAggressive Lymphomas
Hematology NewsBrentuximab vendotin plus CHP meets PFS endpoint in ECHELON-2October 2, 2018T Cell LymphomasAggressive Lymphomas
Hematology NewsFDA lifts partial hold on tazemetostat trialsSeptember 30, 2018T Cell LymphomasLymphoma & Plasma Cell DisordersAggressive LymphomasFollicular LymphomaB Cell LymphomaSarcoma & GIST
